eXIthera Pharmaceuticals
Manufacturing · Massachusetts, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
1900 W Park Dr Ste 280, Westborough, Mas...Phone Number
(508) 983-1436Website
www.exithera.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About eXIthera Pharmaceuticals
eXIthera is a clinical-stage biotech company developing small molecule inhibitors of Factor XIa which offer the potential of thrombosis prevention without the bleeding liabilities which exist for all current treatment options. eXIthera's lead IV candidate, EP-7041, is a novel, potent and selective small-molecule Factor XIa inhibitor. EP-7041 was found to be safe and well tolerated in sixty healthy volunteers following single or multiple ascending doses in a recent Phase 1 clinical study. In addition, the pharmacokinetic and pharmacodynamic profile indicated desired efficacy with minimal potential for bleeding.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is eXIthera Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at eXIthera Pharmaceuticals
Product Launch: Get notified when eXIthera Pharmaceuticals launches new products
Earning: See what the market has to say on eXIthera Pharmaceuticals recently announced quarterly report
eXIthera Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once eXIthera Pharmaceuticals has new funding data
Website visits: Recent activity has been detected on your website
Click to see if eXIthera Pharmaceuticals had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if eXIthera Pharmaceuticals is spiking on competitors!
Check if eXIthera Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Reach out to Masked Content who joined eXIthera Pharmaceuticals as Masked Content
Find 2 more new buyers
Compare Similar Companies to eXIthera Pharmaceuticals
Compare insights from companies similar to eXIthera Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
eXIthera Pharmaceuticals
<$5M
1-10
Private
$17M
2012
N/A
Company Profile Activity
Activity Insights
eXIthera Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
eXIthera Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about eXIthera Pharmaceuticals.
eXIthera Pharmaceuticals financials insights
Gather financial insights about eXIthera Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2012
Series A
$4M
2014
Series B
$10M
2017
Private Equity
$3M
eXIthera Pharmaceuticals Tech Stack
A closer look at the technologies used by eXIthera Pharmaceuticals
See more technologies
eXIthera Pharmaceuticals News & Media
eXIthera Announces Publication of EP-7041 Data Demonstrating Safe Antithrombotic Activity in ECMO
WESTBOROUGH, Mass., Sept. 17, 2020 /PRNewswire/ -- eXIthera Pharmaceuticals, a clinical-stage biotechnology company focused on addressing bleeding complications associated with currently available antithrombotic agents through the inhibition of coagulation Factor XIa, today announced the...eXIthera Appoints Michael Kurz, Ph.D., to Leadership Team
WESTBOROUGH, Mass., June 25, 2019 /PRNewswire/ -- eXIthera Pharmaceuticals, a clinical-stage biotechnology company focused on addressing bleeding complications through the inhibition of Factor XIa, today announced the appointment of Michael Kurz, Ph.D., to the company's leadership team....
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding eXIthera Pharmaceuticals
Sign Up For FreeTo access detailed company insights
eXIthera is a clinical-stage biotech company developing small molecule inhibitors of Factor XIa which offer the potential of thrombosis prevention without the bleeding liabilities which exist for all current treatment options. eXIthera's lead IV candidate, EP-7041, is a novel, potent and selective small-molecule Factor XIa inhibitor. EP-7041 was fo... Read More
